Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) With ABT-494
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Upadacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
- 24 Jul 2017 Planned primary completion date changed from 4 Jun 2017 to 20 Feb 2021.
- 10 Jun 2017 Biomarkers information updated
- 09 Jan 2017 Planned End Date changed from 1 Jul 2020 to 1 Feb 2021.